Dr Reddy's strong product pipeline and other factors that make it stock pick of the week

This post was originally published on this site

Dr Reddy’s Lab (DRL) has reported a decent set of numbers for the third quarter of 2020-21. Its aggregate revenue grew 12% y-o-y; with domestic, US and Europe revenues growing by 26%, 9% and 34% respectively. However, these numbers were lower than the street expectations which led to its share price fall. Analysts say that this lower price is offering a good entry point to this counter. Several short-term catalysts, which can drive growth in